Amgen Pays $240m for Michigan Spinoff’s Dendritic Cell Targeting Molecules for Autoimmune Disorders
January 14, 2021
The multinational biopharmaceutical company Amgen has announced it will pay $240 million in upfront cash and milestone payments for molecules targeting autoimmune conditions from Ann Arbor, MI-based Evoq Therapeutics, a spinoff of research from the University of Michigan. Evoq, founded by Profs. Anna Schwendeman and James Moon, is named for the targeted dendritic cells the company uses to “evoke” immune tolerance in regulatory T cells.
Read more about the pair’s research and their new partnership with Amgen.
Latest News
InterActions: A Lasting Reflection of Michigan Pharmacy
August 18, 2026
When the University of Michigan College of Pharmacy began designing its new home, every detail was considered with purpose — from innovative research spaces to collaborative areas where students, faculty, alumni and visitors could connect.
The building itself was envisioned as more than a place to learn and discover. It would also tell the story of […]
Ashley Kuzmik: Bridging the Gap Between Hospital and Home
August 10, 2026
For many families, the transition from hospital to home after a loved one with dementia is discharged can be overwhelming. New medications, changing symptoms, mobility challenges and the demands of caregiving often converge all at once, leaving families to navigate an already difficult journey. Helping make that transition easier is at the heart of Ashley […]
From Student Support to Endowed Legacy
June 22, 2026
Allen J. Sedman, PhD ’73, MD ’78, and Aileen B. Sedman, MD ’78, have spent their lives utilizing the knowledge imparted by the University of Michigan. In turn, they have expressed their gratitude through gifts bestowed to the College of Pharmacy and the Department of Pediatrics.
Allen Sedman arrived at U-M at a time when pharmacokinetics […]